Valneva starts PhII C. diff trial; EC backs Ebola vaccine consortium for GSK candidate;

> Valneva has kicked off a Phase II trial of its Clostridium difficile vaccine. Report

> The European Commission (EC) has put €15.1 million behind a consortium of leading research institutions devoted to advancing development of GlaxoSmithKline's Ebola vaccine candidate. More

> Seattle researchers have discovered a vaccine candidate that they expect to stimulate the production of neutralizing antibodies that defend against infection from a broad spectrum of HIV strains. Release

> The U.S. Patent and Trademark Office has issued key protection for ImmunoCellular Therapeutics' glioblastoma vaccine. Release

And Finally... A mumps outbreak that has so far affected 15 NHL players on 5 teams "could happen anywhere," experts say. More

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.